A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)

Next Previous
Trial Profile

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors GlaxoSmithKline; Novartis Pharmaceuticals

    • Most Recent Events

    • 06 May 2016 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Mar 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top